3,3-bis(3-fluorophenyl)-N-methylpropan-1-amine;hydron;chloride

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3,3-bis(3-fluorophenyl)-N-methylpropan-1-amine;hydron;chloride
• 化学式: C16H18ClF2N
• 分子量: 297.77
• InChiKey: MGNMVYXIKDNAKK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.13
• 重原子数：
  20
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  12
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  N-benzyl-3,3-bis(3-fluorophenyl)-N-methylprop-2-en-1-amine;hydrochloride 以80的产率得到3,3-bis(3-fluorophenyl)-N-methylpropan-1-amine;hydron;chloride
  参考文献：
  名称：

  Methods and compounds for treating depression and other disorders

  摘要：

  本发明的特点是具有在血清素再摄取位点和N-甲基-D-天门冬氨酸（NMDA）受体活性的化合物，并使用这些化合物治疗不同的疾病。具有在血清素再摄取位点和NMDA受体（“多功能化合物”）的活性的化合物可用于治疗不同类型的疾病，如强迫症障碍（OCD），睡眠障碍，性功能障碍和进食障碍。

  公开号：

  EP1790337A2

文献信息

• Methods and compounds for treating depression and other disorders
  申请人：NPS Pharmaceuticals, Inc.

  公开号：US20040039014A1

  公开（公告）日：2004-02-26

  The present invention features compounds active at both the serotonin reuptake site and the N-methyl-D-aspartate (NMDA) receptor and the use of such compounds for treating different disorders. Compounds having activity at the serotonin reuptake site and the NMDA receptor (“multi-active compounds”) can be used to treat different types of disorders such as depression, obsessive-compulsive disorders (OCD), sleep, disorders, sexual dysfunction, and eating disorders. Preferably, the multi-active compounds are used to treat depression.

  本发明的特点是活性化合物同时作用于5-羟色胺再摄取位点和N-甲基-D-天冬酰胺（NMDA）受体，并利用这些化合物治疗不同的疾病。在5-羟色胺再摄取位点和NMDA受体具有活性的化合物（“多活性化合物”）可用于治疗不同类型的疾病，如抑郁症、强迫症障碍（OCD）、睡眠障碍、性功能障碍和进食障碍。最好是，多活性化合物用于治疗抑郁症。
• Compounds active at a novel site on receptor-operated calcium channels
  申请人：NPS Pharmaceuticals, Inc.

  公开号：US06017965A1

  公开（公告）日：2000-01-25

  Method and compositions for treating a patient having a neurological disease or disorder, such as stroke, head trauma, spinal cord injury, spinal cord ischemia, ischemia- or hypoxia-induced nerve cell damage, epilepsy, anxiety, neuropsychiatric or cognitive deficits due to ischemia or hypoxia such as those that frequently occur as a consequence of cardiac surgery under cardiopulmonary bypass, or neurodegenerative diseases such as Alzheimer's Disease, Huntington's Disease, Parkinson's Disease, or amyotrophic lateral sclerosis (ALS).

  治疗神经系统疾病或障碍的方法和组合物，如中风、头部外伤、脊髓损伤、脊髓缺血、缺血或低氧引起的神经细胞损伤、癫痫、焦虑症、神经心理或认知缺陷，由于缺血或低氧而经常发生于心脏手术下心肺旁路的后果，或神经退行性疾病，如阿尔茨海默病、亨廷顿病、帕金森病或肌萎缩性侧索硬化症（ALS）。
• Nanocarriers and their processing for diagnostics and therapeutics
  申请人：Rhode Island Hospital

  公开号：US10555948B2

  公开（公告）日：2020-02-11

  The compositions and methods of the invention provide compositions and methods for preferential targeting of tissues to delivery therapeutic or diagnostic agents. For example, such compounds are useful in the treatment of joint disorders those affecting articulating joints, e.g., injury-induced osteoarthritis as well as autoimmune diseases affecting joint tissue such as rheumatoid arthritis.

  本发明的组合物和方法提供了优先靶向组织递送治疗或诊断制剂的组合物和方法。例如，这类化合物可用于治疗影响关节的关节疾病，如损伤引起的骨关节炎以及影响关节组织的自身免疫性疾病，如类风湿性关节炎。
• Topical pharmaceutical composition containing phenytoin and a (co-) analgesic for the treatment of chronic pain
  申请人：Topical Innovations B.V.

  公开号：US11147799B2

  公开（公告）日：2021-10-19

  This disclosure relates to a pharmaceutical composition for topical use wherein the active pharmaceutical ingredient consists of the co-analgesic phenytoin and at least one further co-analgesic, and a method for producing the pharmaceutical composition. In addition, the disclosure relates to the pharmaceutical composition for use in the treatment of chronic pain.

  本公开涉及一种局部使用的药物组合物，其中的活性药物成分包括共镇痛剂苯妥英和至少另一种共镇痛剂，还涉及一种生产该药物组合物的方法。此外，本发明还涉及用于治疗慢性疼痛的药物组合物。
• METHODS AND COMPOUNDS FOR TREATING DEPRESSION
  申请人：NPS PHARMACEUTICALS, INC.

  公开号：EP1096926B1

  公开（公告）日：2007-02-28